Novo Nordisk A/S and telehealth company Hims & Hers Health Inc. announced a partnership to jointly market and sell obesity medications, ending a legal dispute that began in February 2026. The announcement was made on March 7, 2026, and follows a lawsuit in which Novo sued Hims & Hers for marketing a compounded Wegovy pill.
Under the co‑sell agreement, the two companies will jointly market Wegovy and Hims & Hers’ compounded semaglutide products. Wegovy will be sold at $599 per month bundled with clinical support, or at $299–$349 per month through NovoCare Pharmacy, with a $499 tier for other platforms. Hims & Hers will continue to offer its compounded version at $49 per month until the partnership terms are finalized.
Specific financial terms of the agreement were not disclosed, but the partnership includes revenue‑sharing arrangements and is expected to last for an unspecified term. Hims & Hers gains access to Novo’s distribution network, while Novo gains a digital sales channel through Hims & Hers’ telehealth platform.
The deal removes a major legal overhang for Hims & Hers, transforming its business model from a contested compounding pharmacy to a licensed distributor of FDA‑approved obesity drugs. For Novo, the partnership expands patient reach in the competitive GLP‑1 market dominated by Eli Lilly, potentially increasing market share.
Following the announcement, Hims & Hers’ stock surged about 40% in after‑hours trading, reflecting investors’ relief at the resolution of regulatory risk and the validation of its platform. Novo’s ADRs rose modestly, indicating confidence in the expanded distribution channel.
The partnership follows a February 2026 lawsuit where Novo sued Hims & Hers for patent infringement over a compounded Wegovy pill. Hims & Hers had withdrawn the product after the lawsuit. The two companies had a brief partnership in 2025 that ended when Novo cited marketing concerns.
The collaboration is expected to strengthen both companies’ positions in the obesity drug market, with Hims & Hers benefiting from higher‑margin branded products and Novo gaining a broader digital footprint. The long‑term impact will depend on the final terms of the co‑sell agreement and the regulatory environment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.